Skip To Main Content
Kristin Jensen on Muck Rack

Kristin Jensen

  • Freelance Journalist and Consultant, Freelance
As seen in: Bloomberg Businessweek, Bloomberg Markets Magazine, Bloomberg News, HuffPost, CQ Researcher, SAGE Publishing, Journal of Medical Case Reports, Mint, Healthcare Dive, CIO Dive and
Chicago girl & Bears fan; freelancer & Bloomberg News vet; opinions are my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kristin

Contact Kristin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evaluation of a Guided Nature and Forest Therapy Walk for Internal Medical Residents – A Brief Report - Katherine T. Morrison, Kristin M. Jensen, Angela Keniston, Lauren McBeth, Amber L. Vermeesch, Kerry “Nellie” O’Connor, 2024

|
By Katherine Morrison, Kristin Jensen, Angela Keniston, Lauren McBeth
| SAGE Publishing
Background Burnout and mental health issues continue to plague healthcare providers, including trainees.1,2 While organizational and system changes are crucial to reversing these concerns, interventions which improve mental health and overall personal wellbeing are needed in the interim.3 Mindfulness has been shown to improve wellbeing in healthcare providers, including medical residents.4,5 Shinrin Yoku (SY), or forest bathing, is a practice that encourages mindfulness through participants’...
Open in Who Shared Issue with article?

Takeda wins US approval for new CMV treatment

|
By Kristin Jensen, Ned Pagliarulo
| BioPharma Dive Verified
Dive Brief: Transplant patients in the U.S. with a common infection now have a new treatment option, with this week's approval of Takeda Pharmaceutical's maribavir, which will be sold in the U.S. as Livtencity. The Food and Drug Administration on Tuesday cleared the medicine for patients with a cytomegalovirus, or CMV, infection that's resistant to other available antiviral treatments. To date, those patients haven't had a fallback treatment option after older drugs stop working.
Open in Who Shared Issue with article?

Roche cuts ties with Atea after COVID-19 pill's trial failure

|
By Kristin Jensen, Ned Pagliarulo
| BioPharma Dive Verified
Dive Brief: Roche is giving up on a partnership with Atea Pharmaceuticals to develop a pill for COVID-19 after the drug disappointed in a clinical trial. The collaboration will officially end on Feb. 10, Atea said in a statement late Tuesday. Still, the Boston-based biotech said it has plenty of cash to keep developing AT-527 on its own and believes the medicine has a role to play in treating COVID-19.
Open in Who Shared Issue with article?
See all 438 licensed articles (439 Total)